Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Gross Margin (2016 - 2026)

Amphastar Pharmaceuticals has reported Gross Margin over the past 13 years, most recently at 46.79% for Q4 2025.

  • For Q4 2025, Gross Margin rose 33.0% year-over-year to 46.79%; the TTM value through Dec 2025 reached 49.46%, down 162.0%, while the annual FY2025 figure was 49.46%, 162.0% down from the prior year.
  • Gross Margin for Q4 2025 was 46.79% at Amphastar Pharmaceuticals, down from 51.42% in the prior quarter.
  • Over five years, Gross Margin peaked at 60.04% in Q3 2023 and troughed at 43.63% in Q1 2021.
  • A 5-year average of 50.02% and a median of 49.96% in 2025 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: skyrocketed 1133bps in 2023 and later plummeted -753bps in 2024.
  • Year by year, Gross Margin stood at 46.52% in 2021, then increased by 13bps to 52.71% in 2022, then rose by 2bps to 53.98% in 2023, then decreased by -14bps to 46.45% in 2024, then increased by 1bps to 46.79% in 2025.
  • Business Quant data shows Gross Margin for AMPH at 46.79% in Q4 2025, 51.42% in Q3 2025, and 49.59% in Q2 2025.